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Background: It was shown earlier that a number of CD207 positive Langerhans cells was lower in basal cell carcinomas than 
in the normal epidermis. Moreover, benign skin lesions presented a higher number of Langerhans cells when they were compared 
to malignant tumors. Aim: To count Langerhans cells, assessing expression levels of CD1A and CD207 markers in actinic kerato-
sis, basal and squamous cell carcinomas, compared with the normal skin. Comparison of Langerhans cells might give a valuable 
prognostic marker for skin cancer. Methods: Immunohistochemistry and methods of statistics were used. Results: Expression 
of CD1A and CD207 markers was assessed in tumor samples of actinic keratosis, cutaneous basal and squamous cell carcinomas, 
in comparison with the normal skin. In each cohort there were 40 patients (and 11 healthy individuals). We have shown that the num-
ber of Langerhans cells is considerably lower in cutaneous basal and squamous cell carcinomas, compared with their number 
in the normal skin (p < 0.0001). Conclusions: CD1A expression correlated with CD207 expression only in the control group. There 
was no correlation in actinic keratosis, basal and squamous cell carcinoma. This may suggest an alteration of Langerhans cells 
phenotype in skin neoplastic diseases, making the number of Langerhans cells a valuable prognostic factor for skin tumors.
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Actinic keratosis is the most common  precancerous 
sun-related lesion. The incidence of develop-
ment of these lesions increases with age, proximity 
to the equator, and outdoor occupation [1]. Actinic 
keratosis has been recognized as a precursor of can-
cer and precancerous lesions in the past. However, 
today it is considered as an early in situ squamous cell 
carcinoma [2]. Histologically, there is cytological atypia 
in the basal/suprabasal layers of the epidermis. This 
lesion is characterized by the loss of orderly matura-
tion with atypical keratinocytes. There are an increased 
number of mitoses. Parakeratosis and dyskeratosis 
are also common features with the usual appearance 
of elastosis in the dermis.
In the past two decades, a dramatic increase has 
been noted in the incidence of basal and squamous 
cell skin cancer [3]. Skin cancer is the most com-
mon cancer in Europe, United States, and Australia, 
and basal cell carcinoma accounts for approximately 
80% of all skin cancers [4]. Basal cell carcinoma rep-
resents one of the most common cancers worldwide 
and is described as a locally invasive, slow-growing 
cancer which rarely metastasizes. Ultraviolet radiation 
is a major factor in non-melanoma skin cancer patho-
genesis. The vast majority of basal cell carcinomas can 
be successfully treated by standard surgical excision 
before serious complications occur.
Squamous cell carcinoma is relatively common skin 
tumour which, if untreated, generally has a progres-
sive clinical course with development of metastatic 
disease and often a lethal outcome [5]. Histologically, 
lesions may differ in degree from actinic keratosis 
in that in squamous cell carcinoma in situ all epider-
mal layers contain atypical keratinocytes. Invasive 
squamous cell carcinoma is frequently derived from 
actinic keratosis [1].
Because skin lesions are visible and easily acces-
sible, skin cancer provides us with an excellent model 
for studying the growth and development of cancer 
in humans. Furthermore, the carcinogenic agents 
in the skin are well known; in particular, ultraviolet 
radiation which is the most important carcinogen [6].
Langerhans cells are the dendritic cells of the epi-
dermis that were discovered by Paul Langerhans 
in 1868 by gold chloride staining [7]. Langerhans cells 
comprise 3–8% of the total epidermal cell popula-
tion [8]. Epidermal dendritic cells constitute a dense 
network located in the basal and supra-basal layers 
of the epidermis. At basal conditions, Langerhans cells 
are immature dendritic cells located between epithelial 
cells in the skin, nasal, oral, esophageal, pulmonary, 
vaginal, and rectal mucosae [9]. Epidermal dendritic 
cells have traditionally been defined by the presence 
of Birbeck granules. These racket-shaped intracyto-
plasmic organelles are only found in Langerhans cells. 
The function of Birbeck granules is still not completely 
understood, although most studies point toward an ac-
tive role in receptor-mediated endocytosis through 
the C-type lectin (Langerin, CD207) [10]. Epidermal 
dendritic cells are distinguished from other dendritic 
cells subsets by expression of more specific markers, 
such as CD207 [10], E-cadherin [11] and CD1A [12]. 
These mole cules are not only epidermal dendritic 
cells markers; they also play functional roles in various 
aspects of Langerhans cells biology.
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CD1A (NP_001754) is a molecule belonging 
to the highly conserved group of CD1 transmembrane gly-
coproteins. The human CD1 family is structurally related 
to the major histocompatibility complex (MHC) proteins. 
It can form heterodimers with β2-microglobulin [13].
CD207 (Langerin, NP_056532) is a type II trans-
membrane protein. Its carbohydrate-recognition 
domain binds various monosaccharides, including 
fucose, mannose, and N-acetyl-glucosamin in a cal-
cium-dependent manner [14]. CD207 is an endocytic 
receptor that functions as a potent inducer of Birbeck 
granules formation by the zipping and superimposition 
of cell membranes [10].
The CD207 protein is expressed in Langerhans 
cells. Mutations in CD207 gene resulted in inhibition 
of Birbeck granule formation that makes this mo lecule 
a valuable subject of study, especially in the skin 
cancers.
In the present work we report that the expression 
of CD1A and CD207 is lower, and number of Lan-
gerhans cells is considerably decreased in cutaneous 
basal and squamous cell carcinomas, compared with 
their number in the normal skin (p < 0.0001).
MATERIALS AND METHODS
Patient material. The study groups comprised 
40 patients with actinic keratosis, cutaneous basal cell 
carcinoma and squamous cell carcinoma. The mean 
age of patients with actinic keratosis was 70.1 years 
(range 33–94) for a group of 21 women and 19 men; 
with cutaneous basal cell carcinoma — 71.2 years 
(range 46–94) for 22 women and 18 men; and for 
24 women and 16 men with cutaneous squamous cell 
carcinoma — 74.3 years (range 50–94). The control 
group consisted of 11 patients (4 women, 7 men) aged 
from 47 to 92 years (mean 74.9). Patients included 
in the present study had neither systemic diseases nor 
any detected immunological abnormalities and did not 
take any preoperative medication.
Immunohistochemistry. Formalin fixed and 
paraffin embedded tissues (40 samples for each 
skin lesions and 11 samples for the control group) 
were retrieved from the archives. The 4 μm thick 
sections were cut, mounted on slides and dried over-
night at 55 oC. Paraffin was removed with xylene and 
the latter was washed away with ethanol. Endogenous 
 peroxidase was blocked using a 3% solution of hydro-
gen peroxide in methanol. The monoclonal mouse 
antibodies against CD1A (clone 010) and CD207 (NCL-
Langerin) were used to stain tissue sections (dilu-
tion 1:100, both antibodies from DakoCytomation, 
Denmark). Bound antibodies were visualized, using 
the Envision+Peroxidase Kit and the diaminobenzidine 
as a chromogen (DakoCytomation). The sections were 
counterstained with Mayer’s haematoxylin. Stainings 
were examined with magnification (× 400). A number 
of positive cells per 1000 cells were counted.
Statistical analysis. U-Mann — Whitney test, 
Kruskal — Wallis test, Spearman rank correlation test, 
and Wilcoxon test were used for statistical assess-
ments. P-values < 0.05 were considered statistically 
significant. Statistical analysis was performed, using 
Statistica version 8 for Windows.
RESULTS
Analysis of CD1A expression by immuno-
histochemistry. In order to assess an expression 
level of CD1A (NP_001754) and CD207 (NP_056532) 
proteins, tissue sections were stained with the ap-
propriate antibodies. The CD1A positive cells among 
1000 cells were counted. We have found that CD1A 
expression varied between the different neoplastic 
skin diseases, showing the mean of 1.0% in basal 
cell carcinomas, 2.2% in squamous cell carcinomas, 
5.8% in actinic kerato sis, and 4.8% in normal skin, 
respectively. The differences between tumors were 
statistically significant (p < 0.0001) (Table 1). The mean 
of CD1A expression in actinic keratosis was higher 
than the mean value for normal skin, however, this 
difference was not statistically significant (p = 0.083). 
A typical pattern of CD1A expression is shown on Fig. 1.
Table 1. CD1A expression in analyzed groups, scored as a percent per 
1000 cells
Groups Num-ber Min Max Mean
Standard 
deviation
Medi-
an
Basal cell carcinoma 40 0 6.0 1.0 1.0 1.0
Squamous cell carcinoma 40 0 4.0 2.2 1.0 2.0
Actinic keratosis 40 2.1 12.4 5.8 2.0 5.6
Control 11 3.0 8.7 4.8 1.7 4.0
a
b
Fig. 1. A typical pattern of CD1A expression. Less cells showed 
CD1A signal (brown) in squamos cell carcinoma (a), compared with 
normal skin (b). Nuclei are shown in blue. Magnification was ×400
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Analysis of CD207 expression by immuno-
histochemistry. The same tissue sections were 
stained for CD207 in order to monitor the presence 
of Langer hans cells. The CD207 expression was lower 
significantly in all tumors studied, compared with nor-
mal skin (Table 2). In normal skin the CD207 signal was 
detected in 3.7% cells, compared with 2.9% in actinic 
keratosis, 0.8% in squamos cell carcinomas, and 0.5% 
in basal cell carcinomas, respectively (p < 0.0001). 
A representative CD207 staining is shown on Fig. 2.
Table 2. CD207 expression in analyzed groups, scored as a percent per 
1000 cells
Groups Num-ber Min Max Mean
Standard 
deviation
Medi-
an
Basal cell carcinoma 40 0 2.0 0.5 0.5 0.5
Squamous cell carcinoma 40 0 2.0 0.8 0.6 0.9
Actinic keratosis 40 1.0 6.7 2.9 1.0 3.0
Control 11 2.6 4.5 3.7 0.6 4.0
a
b
Fig. 2. A representative CD207 signal in tumor and normal 
tissues. Less cells showed CD207 signal (brown) in basal cell 
carcinoma (a), compared with normal skin (b). Nuclei are shown 
in blue. Magnification was ×400
Statistical analysis of groups. After thorough 
analysis of the data, it was possible to conclude that 
CD1A signal was significantly higher in all groups of pa-
tients in comparison with the CD207 signal (p < 0.05) 
(Table 3).
A high value of CD1A signal followed a high 
CD207 only in the control group (R = 0.652; p = 0.03). 
This correlation was altered in a cases of basal cell 
carcinoma (R = 0.252; p = 0.117), squamous cell 
carcinoma (R = 0.06; p = 0.713), and actinic keratosis 
(R = 0.034; p = 0.835).
Table 3. Comparison of expression of CD1A and CD207 in analyzed 
 tumors compared with normal skin, scored as a percent per 1000 cells 
and presented as a mean value
Diagnosis N CD1A CD207 p
Basal cell carcinoma 40 1.0 0.5 0.004
Squamous cell carcinoma 40 2.2 0.8 < 0.0001
Actinic keratosis 40 5.8 2.9 < 0.0001
Control 11 4.8 3.7 0.025
DISCUSSION
Based on our data it is possible to suggest that 
the number of Langerhans cells that usually express 
CD207 and also CD1A is considerably lower in cutane-
ous basal and squamous cell carcinomas, compared 
with their number in the normal skin. It was shown 
earlier that an incidence of CD207 positive Langerhans 
cells was lower in basal cell carcinomas as compared 
with the normal epidermis [15]. Moreover, benign skin 
lesions presented a higher number of Langerhans 
cells when they were compared to malignant and 
normal skin [16]. We have found similar phenomenon 
also for squamos cell carcinoma and, partially, for ac-
tinic keratosis. Notheworthy, the regressive neoplasm 
of the skin had the greatest dendritic cell infiltration 
compared to progressive neoplasm [17]. It was ob-
served that such decrease in dendritic cell number 
could be a bad prognostic factor for other solid tu-
mors as well. Actually, Langerhans cells density was 
proposed as a prognostic marker for laryngeal squa-
mous cell carcinomas [18] and breast cancer [19]. 
Moreover, the lack of CD1A expression in the dendritic 
cells of Barrett’s mataplasia may predict its evolution 
toward esophageal adenocarcinoma [20]; presence 
of CD1A expressing cells in tumors may influence 
metastasis [15].
In our study, the mean level of CD1A signal was 
significantly higher in all groups of patients than 
the level of CD207 expression (p < 0.05). This could 
be explained by the fact that precursors Langerhans 
cells lack CD207 positive Birbeck granules, the same 
can happen during the migration from the epidermis. 
Therefore, CD1A+ CD207− cells could correspond 
to the replacement cells which have recently reached 
the epithelial compartment and are not yet  expressing 
the CD207, or cells migrating toward the con-
nective tissue, presenting with a down-regulation 
of the CD207 expression [21]. CD1A and CD207 mo-
lecules identify distinctive subpopulations of epithelial 
dendritic cells which express variable immunophe-
notypes that are influenced by the functional stage 
of these cells and the presence of various epithelial 
cytokines. Thus, distinct cytokines could be implicated 
in the induction of CD1A or CD207 expression.
CD1A expression correlated with CD207 expres-
sion only in the control group. There was no correlation 
in actinic keratosis, basal and squamous cell carci-
noma; this may suggest an alteration of Langerhans 
cells phenotype in skin neoplastic diseases. Langer-
hans cells are considered to play an important role 
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in antitumour immunity. Vaccination with dendritic cells 
pulsed with tumour peptides, lysates or RNA, or loaded 
with apoptotic and necrotic tumour cells could induce 
significant antitumour immunity [22]. In the future, 
biomedical researchers and vaccine developers will 
seek to translate further progress in the biology of cu-
taneous dendritic cells into therapeutic indications.
CONCLUSION
Based on our data it is possible to speculate that 
the number of Langerhans cells is considerably lower 
in cutaneous basal and squamous cell carcinomas, 
compared with their number in the normal skin. 
CD1A expression correlated with CD207 expression 
only in the control group. There was no correlation 
in actinic keratosis, basal and squamous cell carci-
noma. This may suggest an alteration of Langerhans 
cells phenotype in skin neoplastic diseases, making 
the number of Langerhans cells a valuable prognostic 
factor in skin tumors.
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